Abstract
Green tea is a beverage consumed around the world that is believed to have substantial health benefits such as reducing the risk of cancer, cardiovascular diseases, diabetes and neurodegeneration. This beverage is prepared from the leaves (steamed and dried) of the Camellia sinesis plant and contains strong antioxidant and neuroprotective phenolic compounds from which the most important is (-)-Epigallocatechin-3-gallate. Parkinson’s disease (PD) is the second more common neurodegenerative disorders, after Alzheimer’s disease and is characterized by degeneration of dopaminergic neurons in the pars compact of the substantia nigra of the basal ganglia. It has been shown in pre-clinical and clinical studies that green tea may be able to prevent PD, but its optimal dose or a possible mechanism explaining its health benefit in PD has not been properly established. In this review, we discuss the potential role of green tea’s phenolic compounds and their therapeutic effectin modulating key signaling pathways in the PD brain.
CNS & Neurological Disorders - Drug Targets
Title:Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease
Volume: 15 Issue: 3
Author(s): Juan C. Jurado-Coronel, Marco Ávila-Rodriguez, Valentina Echeverria, Oscar Alejandro Hidalgo, Janneth Gonzalez, Gjumrakch Aliev and George E. Barreto
Affiliation:
Abstract: Green tea is a beverage consumed around the world that is believed to have substantial health benefits such as reducing the risk of cancer, cardiovascular diseases, diabetes and neurodegeneration. This beverage is prepared from the leaves (steamed and dried) of the Camellia sinesis plant and contains strong antioxidant and neuroprotective phenolic compounds from which the most important is (-)-Epigallocatechin-3-gallate. Parkinson’s disease (PD) is the second more common neurodegenerative disorders, after Alzheimer’s disease and is characterized by degeneration of dopaminergic neurons in the pars compact of the substantia nigra of the basal ganglia. It has been shown in pre-clinical and clinical studies that green tea may be able to prevent PD, but its optimal dose or a possible mechanism explaining its health benefit in PD has not been properly established. In this review, we discuss the potential role of green tea’s phenolic compounds and their therapeutic effectin modulating key signaling pathways in the PD brain.
Export Options
About this article
Cite this article as:
Jurado-Coronel C. Juan, Ávila-Rodriguez Marco, Echeverria Valentina, Hidalgo Alejandro Oscar, Gonzalez Janneth, Aliev Gjumrakch and Barreto E. George, Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease , CNS & Neurological Disorders - Drug Targets 2016; 15 (3) . https://dx.doi.org/10.2174/1871527315666160202125519
DOI https://dx.doi.org/10.2174/1871527315666160202125519 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Oxidative and Nitrosative Stress and Immune-inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)
Current Neuropharmacology Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
Mini-Reviews in Medicinal Chemistry Beta-Caryophyllene, a CB2R Selective Agonist, Protects Against Cognitive Impairment Caused by Neuro-inflammation and Not in Dementia Due to Ageing Induced by Mitochondrial Dysfunction
CNS & Neurological Disorders - Drug Targets MicroRNAs in Neuroblastoma: Biomarkers with Therapeutic Potential
Current Medicinal Chemistry Saponins as Tool for Improved Targeted Tumor Therapies
Current Drug Targets Nitric Oxide Control of MYCN Expression and Multi Drug Resistance Genes in Tumours of Neural Origin
Current Pharmaceutical Design Cannabinoid Receptors as Therapeutic Targets
Current Pharmaceutical Design Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Modulation of Ornithine Decarboxylase Activity by Phenolics Based Structurally Related Compounds Synthesized on Steroidal and Non-Steroidal Skeleton and their Radical Scavenging Action
Current Bioactive Compounds Amyloid Beta Peptide, 4-Hydroxynonenal and Apoptosis
Current Alzheimer Research Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer’s Disease
Current Medicinal Chemistry Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry A Phosphoproteomics Approach to Identify Candidate Kinase Inhibitor Pathway Targets in Lymphoma-Like Primary Cell Lines
Current Drug Discovery Technologies Hepatocyte Growth Factor Signaling in Cancer Metastasis
Current Signal Transduction Therapy Vitamins and Cognition: A Nutrigenomics Perspective
Current Nutrition & Food Science